arrow
P

Paul Foster

arcus biosciences
H指数:27
被引数:2,593

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

88 PEAK-1 (NCT07011719): A Randomized, Double-Blind, Active-Control Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

PEAK-1 (NCT07011719):一项关于卡沙替法尼和卡博赞替尼与安慰剂和卡博赞替尼在晚期透明细胞肾细胞癌患者中进行的随机、双盲、活性对照III期试验

2026-09-020
OAAI
3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)

3 卡德拉替芬单药治疗透明细胞肾细胞癌患者的安全性特征:ARC-20研究(NCT05536141)的合并分析

2026-09-020
OAAI
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

作者勘误:卡塞地非安在肾癌中表现出与HIF-2α生物学相关的持久应答

Nature
IF48.5
2026-08-040
OAAI
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

卡斯特地芬在肾癌中显示出与HIF-2α生物学相关的持久应答

Nature
IF48.5
2026-07-010
OAAI
Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2α inhibitor, in healthy participants

卡萨地芬(casdatifan)的药代动力学、药效动力学和安全性研究,该药物是一种新型缺氧诱导因子-2α抑制剂,研究对象为健康受试者。

2025-07-270
OA
Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor
2024-12-090
PRE
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer

阿特珠单抗联合铂类双药化疗治疗晚期非小细胞肺癌患者的长期生存随访

2018-09-0144
PREAI
Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors
2017-07-0112
PRE